Patients with compensated MASH cirrhosis and Fibroscan&#174; VCTE score &lt;15 kPa: baseline data from a phase 3, double-blinded, randomized clinical trial assessing the safety and efficacy of pegozafermin (ENLIGHTEN-Cirrhosis)

pegozafermin (RG6881) - Roche

https://events-distribution.easl.eu/from.storage?image=X9WvFraREucXDOc3lNmAYNq0o1rhb4hx2jmLlufmfrPuKqDgAsoOOvXP67ontBjb0

Rohit Loomba1; Naim Alkhouri2; Quentin M. Anstee3; Hank Mansbach4; Cynthia L. Hartsfield4; Laura Contreras4; Jasmine Dowlat4; Jennifer B Kang4; Shibao Feng4; Maya Margalit4

Mar 18, 2026